{{Drugbox
| IUPAC_name = ''N''-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1''H''-indole-3-carboxamide 
| image = 5F-ADBICA_structure.png

<!--Clinical data-->
| tradename =  
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category =  
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = Schedule II
| legal_UK = <!-- GSL         / P       / POM / CD / Class A, B, C -->
| legal_US = <!-- OTC                   / Rx-only  / Schedule I, II, III, IV, V -->
| legal_status =
| routes_of_administration =

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =

<!--Identifiers-->
| CAS_number_Ref = 
| CAS_number = 1801338-27-1
| ATC_prefix = 
| ATC_suffix = 
| PubChem = 
| ChemSpiderID = 29342128

<!--Chemical data-->
| C=20 | H=28 | N=3 | O=2 | F=1
| molecular_weight = 361.46 g/mol
| smiles = FCCCCCn1cc(c2c1cccc2)C(=O)NC(C(C)(C)C)C(=O)N
| StdInChI = 1S/C20H28FN3O2/c1-20(2,3)17(18(22)25)23-19(26)15-13-24(12-8-4-7-11-21)16-10-6-5-9-14(15)16/h5-6,9-10,13,17H,4,7-8,11-12H2,1-3H3,(H2,22,25)(H,23,26)
| StdInChIKey = ITZSOCZDFSHNCL-UHFFFAOYSA-N
}}

'''5F-ADBICA''' (also known as '''5F-ADB-PICA''') is an [[indole]]-based [[synthetic cannabinoid]] that is a potent [[agonist]] at [[CB1 receptor|CB<sub>1</sub> receptors]] and [[CB2 receptor|CB<sub>2</sub> receptors]] with EC<sub>50</sub> values of 0.77 nM and 1.2 nM respectively.<ref>{{cite journal | url=http://pubs.acs.org/doi/abs/10.1021/acschemneuro.5b00112 | title=The pharmacology of indole and indazole synthetic cannabinoid designer drugs AB-FUBINACA, ADB-FUBINACA, AB-PINACA, ADB-PINACA, 5F-AB-PINACA, 5F-ADB-PINACA, ADBICA and 5F-ADBICA | author=Samuel D Banister | author2=Michael Moir | author3=Jordyn Stuart| author4=Richard C Kevin | author5=Katie E Wood| author6=Mitchell Longworth | author7=Shane M Wilkinson| author8=Corinne Beinat | author9=Alxendra S Buchanan| author10=Michelle Glass | author11=Mark Connor| author12=Iain S McGregor | author13=Michael Kassiou | journal=ACS Chemical Neuroscience |date=July 2015  | doi=10.1021/acschemneuro.5b00112 | pmid=26134475 | volume=6 | pages=1546–59}}</ref><ref>{{cite web | url=http://forendex.southernforensic.org/index.php/detail/index/1262 | title=5F-ADBICA | publisher=Southern Association of Forensic Scientists | accessdate=21 July 2015}}</ref>

==Legal Status==

===China===
As of October 2015 5F-ADBICA is a controlled substance in China.<ref>{{cite web | url=http://www.sfda.gov.cn/WS01/CL0056/130753.html | title=关于印发《非药用类麻醉药品和精神药品列管办法》的通知 | publisher=China Food and Drug Administration | date=27 September 2015 | language=Chinese | accessdate=1 October 2015}}</ref>

==See also==
{{div col|colwidth=30em}}
* [[ADBICA]]
* [[ADB-PINACA]]
* [[APICA]]
* [[PX-1]]
* [[SDB-001]]
* [[STS-135 (drug)|STS-135]]
{{Div col end}}

==References==
<references/>

{{Cannabinoids}}

[[Category:Cannabinoids]]
[[Category:Designer drugs]]
[[Category:Indoles]]
[[Category:Indolecarboxamides]]


{{cannabinoid-stub}}